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Abstract
Background: Severe disease caused by 2009 pandemic influenza A/H1N1virus is characterized by the presence of
hypercytokinemia. The origin of the exacerbated cytokine response is unclear. As observed previously, uncontrolled
influenza virus replication could strongly influence cytokine production. The objective of the present study was to
evaluate the relationship between host cytokine responses and viral levels in pandemic influenza critically ill
patients.
Methods: Twenty three patients admitted to the ICU with primary viral pneumonia were included in this study. A
quantitative PCR based method targeting the M1 influenza gene was developed to quantify pharyngeal viral load.
In addition, by using a multiplex based assay, we systematically evaluated host cytokine responses to the viral
infection at admission to the ICU. Correlation studies between cytokine levels and viral load were done by
calculating the Spearman correlation coefficient.
Results: Fifteen patients needed of intubation and ventilation, while eight did not need of mechanical ventilation
during ICU hospitalization. Viral load in pharyngeal swabs was 300 fold higher in the group of patients with the
worst respiratory condition at admission to the ICU. Pharyngeal viral load directly correlated with plasma levels of
the pro-inflammatory cytokines IL-6, IL-12p70, IFN-g, the chemotactic factors MIP-1b, GM-CSF, the angiogenic
mediator VEGF and also of the immuno-modulatory cytokine IL-1ra (p < 0.05). Correlation studies demonstrated
also the existence of a significant positive association between the levels of these mediators, evidencing that they
are simultaneously regulated in response to the virus.
Conclusions: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the
existence of a direct association between viral replication and host cytokine response, revealing a potential
pathogenic link with the severe disease caused by other influenza subtypes such as H5N1.
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Two years later, the pathogenesis of the illness caused by
2009 pandemic influenza is still poorly known. Pregnancy,
severe obesity, cardiovascular disease and diabetes have
been reported as risk factors for critical illness following
infection with the pandemic virus [1,2]. Persistence of viral
secretion has been found in the patients with the worst
outcomes [3-5]. Prompt antiviral treatment has been
recognized as a protective factor [6]. A number of studies
report increased and persistent levels of cytokines and
chemokines paralleling severe disease [7,3,8]. A exacer-
bated cytokine response can contribute to immune-
mediated tissue damage during viral infections [9,10]. In
this sense, unregulated cytokine and interferon responses
have been described to parallel persistence of viral replica-
tion and severe disease in SARS [11]. The cause of the
observed hypercytokinemia in severe 2009 pandemic influ-
enza is unclear. As previously described, uncontrolled
influenza virus replication could strongly influence cyto-
kine production [5,12,13].
The objective of the present study was to evaluate the
relationship between host cytokine responses and phar-
yngeal viral load in pandemic influenza critically ill
patients at admission to the ICU.
Methods
Patients
Twenty three patients attending the participants’ ICUs
with primary viral pneumonia during the acute phase of
influenza virus illness with negative respiratory and blood
bacterial cultures at admission were recruited from
November 1
st to December 31
st 2009. Only those patients
with confirmed H1N1 infection by real-time polymerase
chain reaction (PCR) were included in the study. Blood
samples for plasma and serum were collected by using
serum, ethylenediaminetetraacetic acid (EDTA) venous
blood vacuum collection tubes following the manufac-
turer’s instructions in the next 24 hours following admis-
sion to the ICU, according to a unified protocol for all the
participant centers. A pharyngeal sample was collected in
parallel. Fifteen healthy volunteers of similar age to the
patients were recruited among workers of the University
of Valladolid, Spain. A standard survey was employed to
collect the clinical data, including history and physical
examination, oximetric measurement, haematological, bio-
chemical, radiological and microbiological investigation in
all the participant centers. Treatment decisions for all
patients were not standardized and were decided by the
attending physician. Informed consent was obtained
directly from each patient or their legal representative and
also from the healthy controls before enrolment. Patient
and control identification remained anonymous. Approval
of the study protocol in both the scientific and the ethical
aspects was obtained from the Scientific Committees for
Clinical Research of each one of the participant centers.
Samples were stored at -80°C until viral load quantifica-
tion, cytokine and antibody profiling. Patients were split
into two groups, depending on the severity of the respira-
tory failure. The MV group underwent intubation and
ventilation (n = 15); the NMV group was composed of
eight patients not requiring mechanical ventilation during
ICU hospitalization.
Microbiology
Viral diagnosis was performed on RNA from pharyngeal
swabs in the Microbiology Services of the participant
hospitals by reverse transcription-polymerase chain reac-
tion (RT-PCR)-based methods using reagents provided
free of charge by the Centers for Disease Control (CDC,
Atlanta, GA, USA) or purchased from Roche (Basel,
Switzerland) (H1N1 detection set). These samples were
also assessed by multiplex PCR (Luminex) with the
xTAG RVP kit from Luminex-Abbott for co-infection
with respiratory syncytial virus, influenza B virus,
parainfluenza viruses 1-4, human metapneumovirus,
enteroviruses, rhinovirus, adenovirus, bocavirus and cor-
onaviruses NL63, HKU1, 229E, OC43, in accordance
with the manufacturer’s instructions. Viral load was
quantified in pharyngeal swabs and plasma in the Virol-
ogy Lab of the WHO associated center at Hospital
Clinic in Barcelona, Spain. A first single real time RT-
PCR was performed for influenza A viral load quantifi-
cation with a set of primers and probes specific for the
influenza virus matrix protein (M1) gene [14]. A stan-
dard graph was constructed from the threshold cycle
values obtained from serially diluted cRNA control.
cRNA control was manufactured from PCR product
cloned into plasmid (pGEM-T Easy Vector System, Pro-
mega). This plasmid contained a T7 RNA polymerase
promoter upstream of the insert to drive transcription
by this enzyme. Previous to be in vitro transcribed using
MEGAscript Kit (Ambion), the plasmid was linearized
with a restriction enzyme (SpeI, New England Biolabs)
downstream of the insert. With an additional DNase
treatment any residual DNA was removed from RNA
transcript. Finally RNA was purified using MEGAclear
Kit (Ambion). The concentration and purity of the RNA
control was calculated by measuring OD260/280.
Known RNA control was serially diluted ten-fold in
sterile water for use in real time PCR. The limit of
detection was 1.86 log10 RNA copies/reaction with a
98.3% efficiency (data not shown). Oseltamivir resistance
was directly detected in the initial positive pharyngeal
swab by RT-PCR and sequencing of a 1296-bp fragment
of the neuraminidase gene for the presence of the muta-
tion H274Y by using an ABI 3130XL Genetic Analyzer.
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to assess the presence of bacterial and fungal infection
[15], along with detection of urinary antigen test to
Legionella pneumophila or Streptococcus pneumoniae.
Hemagglutination inhibition assays (HAI)
HAI assays were performed on a 100-μl aliquot of the
samples at University Health Network (UHN), Toronto,
Ontario, Canada. as previously described [16] using
inactivated pandemic influenza A/California/07/2009
antigens [17].
Immune mediator profiling
Immune mediator levels in plasma were measured in
patients and controls by using the multiplex Bio-Rad 27-
plex assay (Hercules, CA, USA) at the Infection & Immu-
nity Medical Investigation Unit (IMI), HCUV-IECSCYL,
Valladolid, Spain. This system allows for quantitative mea-
surement of 27 different chemokines, cytokines, growth
factors and immune mediators while consuming a small
amount of biological material. A number of additional
soluble mediators were measured by using enzyme-linked
inmunosorbent assays (ELISAs): IFN-a (Verikine kits
purchased from Pbl Interferon Source, Piscataway, NJ,
USA), IL-23, TGF-b1 (Quantikine kits purchased from
R&D Systems, Minneapolis, MN, USA), IL28A (Legend
Max kit purchased from BioLegend, San Diego, CA, USA).
Immune mediator’s concentration of each individual sam-
ple was normalized against the median of the concentra-
tion of the control group (n = 15), and the resultant ratios
were compared between groups of patients.
Statistical analysis
The Mann-Whitney U test was employed for cytokine
comparison purposes, since the Saphiro Wilk test evi-
denced absence of normal distribution of the data, and the
Levene test demonstrated absence of homogeneity of var-
iance in both MV and NMV groups. Correlation studies
between cytokine levels, viral load and clinical parameters
were done by calculating the Spearman correlation coeffi-
cients. Fisher’s exact test was employed for comparing
proportion of fatal cases between patients receiving or not
steroids. All statistical tests were two-sided, and P < 0.05
was considered significant.
Results
Clinical data (table 1)
Chronic respiratory disease and smoking were the most
frequent accompanying medical conditions in our cohort.
Three women were pregnant (one of them was under-
going the second trimester of pregnancy and the other
two the third one). Patients were admitted to ICU five
days in average following the onset of the symptoms (both
groups). Patients in the MV group showed the most severe
respiratory status at admission, based on their Pa O2/Fi
O2 values and SOFA scores. The appearance of bilateral
infiltrates in chest X- Rays was a common finding in both
groups (MV and NMV). Our patients showed elevated
levels of AST and CPK at the first contact with the critical
care services. Lymphopenia was observed in all but three
MV patients and one NMV. All patients received antiviral
treatment (oseltamivir) upon admission to the ICU. Six
out of fifteen MV patients (40.0%) received steroidal treat-
ment in the first 24 hours following admission to the ICU
for six out of eight patients in the NMV group (75%). As
already mentioned, patients did not show clinical or
microbiological signs of bacterial infection at admission to
the ICU. Bacterial super infection during the hospitaliza-
tion period was observed in four out of fifteen (26%) MV
patients. No patients in the NMV group suffered from
bacterial infection during hospitalization. Based on
Hemagglutination Inhibition Assay (HAI), only four
patients (two MV and two NMV) had developed specific
antibodies against pandemic influenza at the time of
admission to the ICU. MV patients stayed longer at the
ICU than NMV patients. Seven MV patients finally died,
while all NMV patients survived. No differences were
found in the proportion of fatal cases between the patients
who received early treatment with steroids (n = 2 fatal
cases) and those who did not receive that treatment (n = 5
fatal cases), p >0 . 0 5 .
Virology
Co-infection by other respiratory viruses was excluded in
all the recruited patients. Viral load in pharyngeal swabs
(copies/ml) was 300 fold higher in the group of patients
with the worst clinical condition (MV) at admission to the
ICU (Figure 1). [Median, inter-quartile range]: MV [53925,
129143.75]; NMV [176.81, 4340.47]. When pharyngeal
viral load was compared between those patients who
received steroids in the first 24 hours following admission
to the ICU and those who did not, absence of significant
differences between both groups of patients was found.
Almost half (7/15) MV patients showed detectable virus in
plasma for only one of the NMV patients. Individual
values of viral load in plasma in the MV group (copies/ml)
were: (1467.5), (348.7); (1423.7); (1656.2); (1276.2); (930.0);
(982.5), the last three values corresponding to three
patients who eventually died. The NMV patient with
detectable virus in plasma showed a viral load of 236.25
copies/ml. We found no significant correlation between
viral RNA load in plasma and APACHE II severity score
at admission. Mutation H275Y in the neuraminidase gene
(NA) was found in one sample collected from a MV male
patient who had received oseltamivir (150 mg/24 h) for
three days before ICU admission. This patient finally died
ten days after the onset of the symptoms and six days after
admission to the ICU. Partial NA sequence was uploaded
Almansa et al. BMC Infectious Diseases 2011, 11:232
http://www.biomedcentral.com/1471-2334/11/232
Page 3 of 9to GenBank database with Accession Number CY064798.
The haemagglutinin (HA) mutations D222G/D222N were
detected in viral samples obtained from five out of fifteen
o ft h em o s ts e v e r ep a t i e n t s :t h r e eo ft h e s ec a s e ss h o w e d
the D222G variation (all of them showed detectable virus
in plasma and one finally died) while two fatal cases
showed the D222N mutation (one of them showed detect-
able virus in plasma). In the NMV group, only one patient
showed the D222G variation. MV patients with the viral
mutation D222G/N did not show differences in pharyn-
geal viral load compared to those MV patients for whom
this mutation was absent..
Table 1 Clinical characteristics of ventilated and non ventilated patients
MV (n = 15) NMV (n = 8)
Gender (M/F) 8/7 1/7
Age 47.00 (15.55) 37.50 (15.12)
Pandemic influenza vaccine (yes/no) 0/15 0/8
Chronic respiratory disease (yes/no) 3/12 2/6
Renal disease (yes/no) 1/14 2/6
Cardiovascular disease (yes/no) 2/13 0/8
Neurological disease (yes/no) 3/12 1/7
Cancer (yes/no) 0/15 1/7
Obesity (BMI > 30) (yes/no) 1/14 1/7
Diabetes (yes/no) 2/13 0/8
Pregnancy (yes/no) 1/14 2/6
Dyslipemia (yes/no) 2/13 0/8
Alcoholism (yes/no) 0/15 2/6
Smoker (yes/no) 9/6 4/4
Fatal outcome/survivors 7/8 0/8
Duration of symptoms at ICU admission 4.9 (3.6) 5.0 (2.2)
Pa O2/Fi O2 120.9 (55.5) 153.8 (69.7)
Days at hospital 20.9 (26.2) 4.5 (1.9)
Days since onset to intubation 5.1 (3.7) n.a
Oseltamivir 15/0 8/0
Duration of symptoms before oseltamivir 4.8 (3.7) 4.6 (2.4)
Bilateral infiltrates in chest X-Ray at admission to ICU (yes/no) 14/1 6/2
Bacterial overinfection during hospitalization (yes/no)
(resp culture-RC; hemoculture-HC)
4/11
S. marcescens RC,
HC
S. aureus RC
P. aeruginosa RC
A. baumanii RC
0/8
Presence of specific antibodies against 2009 pandemic influenza at admission to ICU (titre > 1/40)
(yes/no)
2/13 2/6
SOFA 6.4 (2.8) 4.0 (1.0)
Creatinine (ref value: 0.5 - 1.2 mg/dl) 0.8 (0.4) 1.9 (3.0)
AST (ref value: 2-38 U/l) 91.2 (65.3) 73.8 (39.9)
ALT (ref value: 2-41 U/l) 43.1 (31.0) 75.6 (59.9)
CPK (ref value: 24- 194 U/ml) 850.7 (827.0) 449.0 (697.8)
Leucocytes (4500-10000/mm
3) 6277.8 (3189.6) 7258.7
(3973.6)
Neutrophils (1900-8000/mm
3) 5431.0 (2888.6) 6268.6
(3771.4)
Lymphocytes (900-5200/mm
3) 691.5 (445.6) 636.5 (340.8)
Gender: M: male, F: female. Obesity is considered as Body Mass Index, BMI > 30. PaO2 = pressure of oxygen in arterial blood; FiO2 = fraction of inspired oxygen.
Bacterial culture notation: R.C: respiratory culture; HC: hemoculture. SOFA: Sequential Organ Failure Assessment score. AST: Aspartate transaminase. ALT: Alanine
transaminase. CPK = creatine phosphokinase. Continuous variables are expressed as mean, (standard deviation)
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Comparison of cytokine profiles showed significantly
higher levels of three chemokines (IL-8, MCP-1, MIP-
1b), two cellular growth factors (VEGF, GM-CSF) and
two immuno-modulatory cytokines (IL-1ra, IL-10) in the
M Vg r o u pc o m p a r e dt ot h eN M Vo n e( F i g u r e2a n d3 ) .
In addition, MV patients showed also higher levels of two
Th1 cytokines (IL-12p70, IFN-g) and a pro-Th17 cyto-
kine (IL-6) (p < 0.1), When MV and NMV patients were
considered as one group, the most important increases as
compared to healthy controls corresponded to (mediator,
median fold change compared to control): IL-1RA (6.3),
IP-10 CXCL10 (23.7), IL-6 (22.7), IL-8 (15.5), G-CSF
(5.5), MCP-1 (7.5), IL-10 (5.6) and TGF-b (37.3). On the
contrary, IFN-a,I F N - l (IL-28) and IL-23 were undetect-
able in the vast majority of the patients in both groups.
Comparison of cytokine levels between patients receiv-
ing/not receiving steroids in the first 24 hours following
admission to the ICU revealed significant higher levels in
the latter of IL-1RA, IP-10, VEGF, IL-6, G-CSF, MCP-1,
MIP-1b, IL-12p70 and IFN-g (data not shown).
Spearman test revealed significant positive associations
between the following cytokines and viral load [cytokine,
(r coefficient)]: IL-1ra (0.44), VEGF (0.52), IL-6 (0.46),
MIP-1b (0.65), IL-12p70 (0.50), GM-CSF (0.45), IFN-g
(0.46) (p < 0.05) (Figure 4). Correlation analysis also
demonstrated an association between IL-8 (0.37), MCP-
1 (0.39) and viral load at the level (p < 0.1). When asso-
ciations between plasma levels of IL-1ra, VEGF, IL-6,
MIP-1b, IL-12p70, GM-CSF, IFN-g, IL-8 and MCP-1
were examined, a significant positive correlation was
found between all of them, except for the pair formed
by (IL-8, IL12p70) (data not shown).
Discussion
The relationship between influenza virus and early
host immune response could determine further clinical
outcome. In the present study, patients with severe
Figure 1 Box plot representation of pharyngeal viral load in
ventilated (MV) and non ventilated patients (NMV).
Figure 2 Comparison of cytokine levels in plasma in ventilated (MV) and non ventilated patients (NMV) by box plots. Normalized levels
against control median are showed.
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enza virus showed high levels of viral secretion by the
upper respiratory tract at admission to the ICU, eviden-
cing a poor control of viral replication from the very
first moments in the course of the disease. These results
are in consonance with previous reports showing more
active and prolonged viral replication in severe cases of
both seasonal and pandemic influenza [18,5].
The observed absence of specific antibodies against the
pandemic virus in the vast majority of the patients stu-
died could explain the fail in controlling viral replication.
Lack of protective antibodies against the new virus indi-
cates that most patients were still undergoing the innate
phase of the host response to the virus at the moment of
sampling. In this sense, it is important to highlight that
our cohort was constituted by non vaccinated individuals.
This observation somehow remarks the potential impor-
tance of vaccination for the prevention of severe influ-
enza disease.
Ten patients of this study pertained to a previous
cohort for which cytokine were profiled along the period
of time comprised from disease onset to the moment of
appearance of specific antibodies against the virus [17].
The low number of patients available for inclusion in
that period (8 samples from 4 MV patients and 7 samples
from 6 NMV patients) precluded perhaps to obtain sig-
nificant differences between patients with different
degree of respiratory involvement in that occasion. None-
theless, we consequently found in ventilated patients
higher levels of the same mediators described in the pre-
sent article. In this new work we studied a larger cohort
of patients (n = 23), and cytokine profiles were compared
at a punctual moment in the disease course (admission
to the ICU). This approach evidenced that, at admission,
the most severe patients (MV) showed an exuberant
cytokine and chemokine response, in consonance with
previous reports [3,7,8]. In turn, this new work aimed to
analyze the relationship between viral replication and
host cytokine response. In this sense, the most striking
finding was that, as occurs in human cases of influenza
A/H5N1 infection [13], 2009 pandemic influenza virus
replication is directly associated to the host ‘cytokine
response, pointing to a central role of viral burden in the
pathogenesis of severe forms of this disease.
Correlation studies revealed also that pro and anti
inflammatory cytokines are simultaneously regulated in
response to the virus. MIP-1b and GM-CSF are chemo-
tactic molecules which mobilize neutrophils, monocytes
and macrophages to the site of infection [19]. IL-12p70
and IFN-g are critical contributors to adaptive immunity,
especially in T helper 1 (Th1)-type responses [20,21]. IL-
6 has been reported along with IL-12p70 as markers of
critical pandemic influenza illness [7,8]. VEGF is a potent
angiogenic factor, and is stimulated in hypoxic patients
[22]. In addition, it is thought to increase permeability of
the bronchial airway epithelium following infection by
respiratory viruses [23]. All these mediators are pro-
inflammatory, and in consequence, could play a role in
Figure 3 Comparison of cytokine levels in plasma in ventilated (MV) and non ventilated patients (NMV) by box plots. Normalized levels
against control median are showed.
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Alternatively, they could be neccesary to overcome influ-
e n z ai n f e c t i o ni nt h em o s ts e vere patients. IL-1ra is an
immuno-modulatory molecule. Secretion of IL-1RA
could represent an attempt to prevent cytokine-driven
inflammatory damage or alternatively to represent a
virus-induced evasion mechanism [19,24]. In turn, ele-
vated levels of cytokines such as IL-6 could interfere with
the development of an appropriated adaptive immunity
response to the virus [25,17,26]. Our results confirm in
critically ill patients previous results obtained by Lee et al
in hospitalized patients with 2009 pandemic influenza,
who demonstrated that high plasma levels of IL-6, IL-8,
MCP-1 correlated with the extent and progression of
pneumonia [5].
Conditions such as pregnancy, obesity or chronic
respiratory diseases could influence cytokine production
in response to viral infection [27-29]. Moreover, mechani-
cal ventilation can induce by itself a pro-inflammatory
state in the patient [30]. Steroidal treatment could down-
modulate cytokine responses also, as in fact seem to occur
in our cohort. Nonetheless, a detrimental effect of steroids
has been documented in severe pandemic influenza, asso-
ciated to increased risk of bacterial super-infection in the
treated patients [31,32]. On the contrary, steroidal treat-
ment did not impact on pharyngeal viral load at least at
the time of sampling in our cohort.
The fact that most patients were not treated or had just
begun antiviral treatment at the time of sampling (table 1)
could also explain the exacerbated cytokine response
observed in our patients. One third of the most severe
patients showed the amino acid substitutions D222G/N
in the HA of the virus, which is thought to confer an
increased predilection of the virus for the lower respiratory
tract and has been associated with cases of severe disease
[33,34]. Since only one severe patient was infected by a
virus containing the H275Y mutation in the NA gene, the
potential influence of oseltamivir resistance in the out-
come of our patients is limited, though the single patient
infected with this mutant virus had a fatal outcome.
p= 0.027 p= 0.001
p= 0.015
p= 0.026
p= 0.037 p= 0.012 p= 0.031
Figure 4 Correlations between viral load and cytokines (p < 0.05) (n = 23 patients).
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Severe respiratory disease caused by 2009 pandemic
influenza virus is characterized by the existence of a
direct association between viral replication and host
cytokine response, revealing a potential pathogenic link
with the severe disease caused by other influenza sub-
types such as H5N1.
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